Mineralocorticoid receptor antagonists (MRAs) are evolving as a standard of care for heart failure, with clinicians now choosing between established steroidal agents like spironolactone and the newer nonsteroidal agent finerenone based on patient-specific ejection fraction profiles and comorbid chronic kidney disease.
- Steroidal MRAs (Spironolactone, Eplerenone): Typically utilized for patients with heart failure and reduced ejection fraction (HFrEF) who require standard blockade of aldosterone receptors.
- Nonsteroidal MRA (Finerenone): Now prioritized for patients with heart failure and a left ventricular ejection fraction (LVEF) of 40% or higher, as well as those with chronic kidney disease linked to diabetes.
- Monitoring Requirements: All MRA therapies carry a risk of hyperkalemia (elevated potassium levels), necessitating regular serum electrolyte checks to ensure patient safety.
Heart failure treatment protocols changed after the European Society of Cardiology and the American College of Cardiology issued 2026 clinical guidance, according to Medscape. While spironolactone and eplerenone have long served as the backbone for managing heart failure with reduced ejection fraction (HFrEF), the introduction of finerenone has expanded therapeutic options for patients with heart failure and preserved ejection fraction (HFpEF).
The U.S. Food and Drug Administration (FDA) has granted specific labels for these agents that do not overlap entirely. Aldactone (spironolactone) remains indicated for NYHA class III to IV HFrEF, while Inspra (eplerenone) is specifically cleared for stable patients with HFrEF following an acute myocardial infarction.
Conversely, Kerendia (finerenone) has secured approvals for both heart failure with an LVEF of 40% or higher and for chronic kidney disease associated with type 1 or type 2 diabetes.
Clinical data from major trials highlight the distinct performance of these agents across different patient populations. In the TOPCAT trial, spironolactone did not achieve a statistically significant reduction in the primary composite outcome for patients with an LVEF of 45% or higher, showing a hazard ratio of 0.89 (95% CI, 0.77–1.04).
In contrast, the FINEARTS-HF trial demonstrated that finerenone significantly lowered the rate of total worsening heart failure events and cardiovascular death, with a rate ratio of 0.84 (95% CI, 0.74–0.95).
The American College of Cardiology (ACC) 2026 expert consensus pathway suggests that finerenone should be considered the MRA of choice for HFpEF, with spironolactone serving as a reasonable alternative if cost or medication tolerance becomes a barrier. European Society of Cardiology (ESC) guidelines now provide a Class I, Level A recommendation for MRA use in symptomatic heart failure, regardless of the patient’s LVEF.
| Agent | Primary Indication | Key Trial Result |
|---|---|---|
| Spironolactone | HFrEF (NYHA III-IV) | TOPCAT (HR 0.89; non-significant) |
| Eplerenone | HFrEF (Post-MI, LVEF ≤40%) | Standard post-MI protocol |
| Finerenone | HFpEF (LVEF ≥40%) & CKD | FINEARTS-HF (RR 0.84; significant) |
The primary safety concern across all MRA therapies is the development of hyperkalemia, a condition where serum potassium levels rise above normal limits. In the FINEARTS-HF trial, 14.3% of patients treated with finerenone experienced potassium levels exceeding 5.5 mEq/L, compared with 6.9% in the placebo group. Similarly, the TOPCAT trial reported hyperkalemia in 18.7% of spironolactone recipients versus 9.1% for placebo.
Clinicians must evaluate baseline renal function and potassium levels before initiating therapy. Routine blood work is mandatory for patients to monitor serum potassium and estimated glomerular filtration rate (eGFR) throughout the course of treatment.
While the 2026 guidelines provide a pathway for clinical decision-making, the National Institute for Health and Care Excellence (NICE) has said that no direct head-to-head trials currently exist comparing finerenone with spironolactone in adults with symptomatic chronic heart failure and preserved or mildly reduced ejection fraction. The choice between these agents remains a balance of labeled indications, patient comorbidities, and individual tolerance to steroidal side effects.